Search Results - %22Life+Science%22+and+%22Therapeutics%22+and+%22Small+molecule%22

7 Results

Sort By:

Identification of Galeterone's mechanism of action leading to novel treatment therapies for castrate resistant prostate cancer (CRPC)

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (HRPC), is a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT). The need for effective therapies for these difficult to treat cancers is gaining prominence in the prostate cancer market. The global CRPC market is poised...

Published: 11/19/2020 | Inventor(s): Qingping Dou, Huanjie Yang, Elisabeth Heath

Keywords(s):

Category(s): Life Science, Oncology, Pharmaceuticals, Receptors/targets, Process/Procedure, Small molecule, Therapeutics

Fc-folate conjugate for the treatment of triple negative breast cancer

Approximately 13% of women in the United States will develop breast cancer according to the American Cancer Society. That makes breast cancer the second leading cause of cancer death in women right behind lung cancer. Triple negative breast cancer (TNBC) represents about 10 – 20% of all breast cancers. Triple negative refers to cancer cells...

Published: 12/7/2022 | Inventor(s): Cecilia Speyer

Keywords(s): Anti-cancer, Breast Cancer, Cancer, Cancer Therapies

Category(s): Antibodies, Assays, Biology, Biomedical, Chemical Processing/Synthesis, Diseases, Drug Delivery, Life Science, Oncology, Protein/peptides, Receptors/targets, Small molecule, Therapeutics

Using nanotechnology to target aggressive cancers with a novel small molecule inhibitor of the DNA damage tolerance pathway

Background: Nanotechnology is emerging as a promising tool to target cancer cells. Gold nanoparticles (GNPs) are preferentially taken up by cancer cells when injected into the blood stream and their safety has been demonstrated in human clinical trials. WSU researchers have designed a unique nanoparticle conjugate that combines a GNP with a small molecule...

Published: 8/29/2018 | Inventor(s): Malathy Shekhar, Guangzhao Mao, Yanhua Zhang

Keywords(s):

Category(s): Life Science, Oncology, Small molecule, Receptors/targets, Nano-based, Drug Delivery, Therapeutics, Diseases

A method to identify patients at risk for subsequent stillbirth in the third trimester

A Method to Identify and Treat Patients at Risk for Stillbirth in the 3rd TrimesterWSU Tech#: 12-1113Technology Summary: This invention is a method of identifying patients at risk for subsequent stillbirth (only due to placental related disorder) in the third trimester using a maternal blood sample. A blood sample would be obtained at the beginning...

Published: 1/12/2022 | Inventor(s): Tinnakorn Chaiworapongsa, Roberto Romero, Sonia Hassan

Keywords(s):

Category(s): Medical, Diagnostic, Prenatal, Small molecule, Specialty compounds, Therapeutics, Life Science

Inhibitors of Matrix Metalloproteinases

Wayne State University researchers and academic collaborators have prepared the first reported mechanism-based inhibitors for matrix metalloproteinases (MMPs). One of the novel compounds (SB-3CT) shows selectivity for the gelatinases (two members of the MMP family), which have been implicated in various pathological conditions including, but not...

Published: 11/20/2020 | Inventor(s): Shahriar Mobashery, Rafael Fridman

Keywords(s):

Category(s): Therapeutics, Life Science, Small molecule, Diseases, Oncology

Novel Prenyl Transferase Inhibitors

A series of farnesol and geranylgeraniol analogs that block the prenylation of proteins in cells. The diphosphate derivatives of these compounds are potent inhibitors of protein prenyltransferases in vitro. One allylfarnesol compound specifically inhibits the farnesylation of proteins and one allylgeranylgeraniol compound specifically inhibits the...

Published: 5/19/2017 | Inventor(s): Richard Gibbs

Keywords(s):

Category(s): Therapeutics, Life Science, Small molecule

Novel Hybrid Series of Compound Derived from 2-Aminotetralin and Piperazine Based Derivatives: Characterization for D1, D2, D3, D4 and other Serotonin Receptor Subtypes Binding

A series of compounds derived from 2-aminotetralin and piperazine fragments have been synthesized, which exhibit high CNS activity in vivo and in vitro. Some of the selected lead compounds have exhibited potent in vivo activity in a Parkinson’s disease animal model with long extended duration of action. In particular, these compounds show high...

Published: 11/19/2021 | Inventor(s): Aloke Dutta, Xiang-Shu Fei

Keywords(s):

Category(s): Therapeutics, Diseases, Life Science, Small molecule, Neurological disorders